FY2030 EPS Estimates for Gossamer Bio Cut by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at HC Wainwright decreased their FY2030 earnings per share (EPS) estimates for shares of Gossamer Bio in a report released on Thursday, June 25th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.05 per share for the year, down from their previous estimate of $0.09. HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.45) per share.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.95 million during the quarter, compared to the consensus estimate of $4.67 million.

Several other brokerages also recently weighed in on GOSS. Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd. Oppenheimer dropped their price target on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research note on Thursday, March 5th. Finally, Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Gossamer Bio has an average rating of “Hold” and an average target price of $4.50.

Gossamer Bio Stock Down 2.2%

GOSS stock opened at $0.17 on Friday. Gossamer Bio has a twelve month low of $0.14 and a twelve month high of $3.87. The stock has a market capitalization of $38.77 million, a price-to-earnings ratio of -0.21 and a beta of 2.00. The firm’s fifty day simple moving average is $0.26 and its two-hundred day simple moving average is $1.29.

Institutional Trading of Gossamer Bio

A number of large investors have recently modified their holdings of the company. Tudor Investment Corp ET AL grew its stake in Gossamer Bio by 7.8% in the third quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock worth $132,000 after purchasing an additional 3,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Gossamer Bio by 24.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,964 shares of the company’s stock valued at $74,000 after purchasing an additional 4,767 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Gossamer Bio by 22.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after purchasing an additional 4,771 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of Gossamer Bio by 0.4% in the 4th quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock worth $3,981,000 after buying an additional 5,414 shares during the period. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in shares of Gossamer Bio by 52.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after buying an additional 8,239 shares during the period. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.